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Abstract
Atherogenic modified low- density lipoprotein (LDL) induces pronounced accumulation of cholesterol and lipids in
the arterial wall, while native LDL seems to lack such capability. Therefore, modified LDL appears to be a major
causative agent in the pathogenesis of atherosclerosis. Possible modifications of LDL particles include changes in
size and density, desialylation, oxidation and acquisition of negative charge. Total LDL isolated from pooled plasma
of patients with coronary atherosclerosis, as well as from healthy subjects contains two distinct subfractions:
normally sialylated LDL and desialylated LDL, which can be isolated by binding to a lectin affinity column. We
called the desialylated LDL subfraction circulating modified LDL (cmLDL). In this study, we focused on lipid
composition of LDL particles, analysing the total LDL preparation and two LDL subfractions: cmLDL and native LDL.
The composition of LDL was studied using thin-layer chromatography. We found that cmLDL subfraction had
decreased levels of free and esterified cholesterol, triglycerides, phospholipids (except for lysophosphatidylcholine)
and sphingomyelin in comparison to native LDL. On the other hand, levels of mono-, and diglycerides,
lysophosphatidylcholine and free fatty acids were higher in cmLDL than in native LDL. Our study demonstrated
that lipid composition of cmLDL from atherosclerotic patients was altered in comparison to healthy subjects. In
particular, phospholipid content was decreased, and free fatty acids levels were increased in cmLDL. This
strengthens the hypothesis of multiple modification of LDL particles in the bloodstream and underscores the
clinical importance of desialylated LDL as a possible marker of atherosclerosis progression.
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Background
Atherosclerosis is triggered by lipid accumulation in
subendothelial arterial cells [1]. Intracellular lipid
accumulation is caused by low-density lipoprotein (LDL)
circulating in human blood. It has been demonstrated
that only modified lipoprotein, but not native LDL, can
cause intracellular lipid accumulation in human arterial
wall cells [2]. Although oxidation remains the most
studied atherogenic modification of LDL, other modified
LDL forms were detected in the blood of atherosclerotic
patients. These modifications have not received much
attention so far, but may be highly relevant for the
development of atherosclerosis. Study of the total LDL
from the blood of atherosclerotic patients revealed the
presence of desialylated LDL particles with atherogenic
properties [2]. Glycosphingolipids in LDL have a
terminal sialic acid residue. After removal of sialic acid,
galactose becomes the terminal saccharide. We took
advantage of this fact to isolate the subfraction of desia-
lylated LDL from total LDL preparation using Ricinus
communis agglutinin (RCA120), which possesses a high
affinity to the terminal galactose. Total LDL preparation
was applied on a column with RCA120 immobilized on
CNBr-activated agarose. Normally sialylated LDL passed
through the column without binding to the sorbent.
Desialylated LDL was bound to lectin and then eluted
with 5–50 mM galactose. This method allowed us
isolating subfactions of both sialylated and desialylated
LDL from the total LDL preparation obtained from the
blood of atherosclerotic patients. The latter subfraction
is referred to as circulating modified LDL (cmLDL) [2].
In this work we focused on lipid composition of cmLDL
particles in comparison with native LDL.
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Study subjects included men and women aged 30 to 60
with angiographically demonstrated atherosclerosis and
healthy donors aged 25 to 55 with no signs of ischemic
heart disease according to Rose questionnaire [3, 4]. The
study was approved by the local ethics committee of the
Institute of General Pathology and Pathophysiology
(Moscow, Russian Federation). Cholesterol and triglycer-
ides in blood plasma of study subjects did not exceed
200 mg/dl and 150 mg/dl respectively. Individuals with
diabetes and arterial hypertension were excluded from
the study.
Preparation of blood plasma and serum
Blood samples were drawn in the morning after a night
of fasting using tubes with 1 mg/ml EDTA, 0.38 %
sodium citrate or 10 u/ml sodium heparin (final concen-
trations). Samples were centrifuged for 10 min at 800 g
in 5 mM of phenylmethylsulfonyl fluoride (PMSF), 1 mM
ε-aminocapronic acid and 0.01 % sodium azide. Serum
was obtained by incubation of blood samples for 1 h at
37 °C followed by centrifugation for 15 min at 800 g.
Total LDL preparation
Total LDL fraction was prepared as described previously
[5] or using the method established by our group. 8 ml
of plasma or serum was overlayed by 2 ml of NaBr
solution with density 1.019 g/ml in isotonic phosphate
buffer in a centrifuge tube and centrifuged first for 18 h
at 12 °C (40000 rpm using 50Ti rotor, Beckman Instru-
ments, USA). 2 ml of the upper fraction was accurately
collected and the remaining volume was brought to the
density of 1.070 g/ml with solid NaBr. Next, 2 ml of
NaBr solution with density 1.065 g/ml was accurately
layered on top of the resulting solution and the tube was
centrifuged for 24 h at 12 °C (40000 rpm). 2.5 ml of
solution containing LDL were collected from the top of
the tube and dialysed against 6000 volumes of phosphate
buffer with 10 μM EDTA for 24 h. The solution was
filter-sterilized and stored in plastic tubes at 4 °C for 1
to 2 weeks. We have developed a faster (4.5 – 5 h)
method of total LDL extraction. Blood plasma was
brought to density of 1.390 g/ml with solid NaBr (2 g/ml
of plasma), and 4 ml of plasma was put into a centrifuge
tube. 6 ml of NaBr solution with density 1.019 g/ml was
layered on top and the tube was centrifuged for 2 h
(40000 rpm). The upper 2 cm of liquid containing float-
ing LDL were collected, 2 g/ml of NaBr was added to
the solution, and the tube was centrifuged again in
identical conditions. The obtained LDL samples were di-
alyzed and stored as described above. The LDL fractions
obtained by the two methods had similar physical and
chemical properties [6].
Lectin chromatography of modified LDL
ApoB contains 2 types of oligosaccharide conjugates: oli-
gomannoside and terminally sialylated [7, 8]. Glyco-
sphingolipids in LDL also have a terminal sialic acid
residue [9]. Desialylation will result in the exposure of
the next residue of the carbohydrate chain, which is
galactose. Correspondingly, we hypothesized that desia-
lylated LDL will interact with galactose-specific lectins,
such as Ricinus communis agglutinin (RCA120) [10]. To
prepare the affinity columns, RCA120 was immobilized
on CNBr-activated agarose as described earlier [11]. The
columns were equilibrated with 10–15 ml of isotonic
phosphate buffer, pH 7.2, and 0.5 – 5 ml of LDL sample
(containing 0.2 to 10 mg of protein) was loaded on the
column. The major part of unbound LDL was washed
from the column in the first 10 volumes of phosphate
buffer. Desialylated LDL was washed from the column
with galactose solutions in phosphate buffer (5, 10, 20,
50 and 100 mM). Washing with 50 mM galactose
resulted in virtually complete elution of LDL in the first
5 volumes and this concentration was used most often
[12]. Bound and unbound LDL fractions were brought
to the density of 1.070 g/ml with NaBr, concentrated by
ultracentrifugation and dialyzed against 6000 volumes of
isotonic phosphate buffer as described above.
Lipid analysis
Total lipids were extracted from LDL using a previously
described method [13] in chloroform-methanol 1:2 (v/v)
mixture. 20 μl of 14C-labelled cholesterol in methanol
(1 μCi/ml) was added to samples for future low
correction. 450 μl of chloroform:ethanol solution in 1:2
ratio (volumetric) were added to samples and vigorously
shaked afterwards. Then the samples were incubated in
tubes with closed lids for 2 h at room temperature. The
mixtures were then centrifuged at 4500 rpm for 15 min
and supernatant was transferred to another tube.
Residue was resuspensed in 120 μl of distilled water.
450 μl of chloroform:methanol in 1:2 ratio solution was
added and lipid extraction and centrifugation routine
was repeated as described above. Supernatants were
combined and 600 μl of a mix of chloroform:water 1:1
ratio (volumetric) was added. The samples were then
vigorously shaken and centrifuged for 10 min at
4500 rpm. Then chloroform phase was extracted, diluted
with benzol and evaporated in vacuum in exicator till dry
residue left, which was subsequently dissolved in 50 μl of
mix chloroform:methanol in 2:1 ratio (volumetric) and
stored in closed glass tubes at −20 °C till the analysis of
lipid content of the samples was conducted. Main classes
of lipids in LDL were determined using thin-layer
chromatography. Lipids extracted from LDL and lipid
standards. In order to quantify losses we applied 20 μl of a
14C labelled cholesterol in methanol solution (1 μCu/ml).
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Chromatography for neutral lipids was conducted in a
hexane – diethyl ester – acetic acid 80:20:1 (volumetric)
workflow in a glass chamber filled with solvent vapour for
vertical thin-layer chromatography with ground-in lid.
Then the plate was scanned on Shimadzu CS-930
(Shimadzu, Japan) densitometer at 200 nm wavelength
and lipid content was calculated based on the area of
peaks. Next, neutral lipids were eluted twice up to the top
of the plate using hexane-acetone in 1:3 volumetric ratio
and then again scanning at 200 nm wavelength was used.
Having determined position of the common peak of the
neutral lipids, areas of silicagel concordant with the peak
of each sample were scratched out from the plate and
transferred into glass scintillation flasks, containing 15 ml
of scintillation liquid and put into liquid scintillation
counter 1215 Rackbeta LKB (LKB, Sweden). Main lipid
classes content of LDL were calculated considering in
mind the losses that took place during extraction.
Determination of main phospholipids fractions content
in LDL has also been performed using a densitometer.
Residual after elimination of neutral lipids phospholipids
were eluted in workflow chloroform – methanol – acetic
acid – water in 25:15:4:2 ratio (volumetric) and analyzed
on Shimadzu CS-930 (Shimadzu, Japan) densitometer at
200 nm wavelength.
Results
We performed quantitative analysis of the main classes
of neutral lipids in native LDL and cmLDL from healthy
donors and coronary atherosclerosis patients. In cmLDL
from healthy donors, free and esterified cholesterol and
triglycerides levels were 30 – 40 % lower in comparison
to native LDL (Fig. 1). On the other hand, monoglycer-
ides and free fatty acid levels in cmLDL were 1.5-fold
higher than in native LDL (Fig. 2). In cmLDL from
atherosclerotic patients, contents of free and esterified
cholesterol and TGs were 1.5 to 2 fold lower, and levels
of mono- and diglycerides and free fatty acids – 3 to 4
fold higher than in native LDL. cmLDL from athero-
sclerotic patients contained less phosphatidylcholine,
phosphatidylethanolamine and sphingomyelin and more
lysophosphatidylcholine than native LDL (Fig. 3). Levels
of major classes of phospholipids in native LDL from
atherosclerotic patients were similar to those in native
LDL from healthy donors.
Discussion
Desialylation is likely to be the first or one of the first
steps in the chain of multiple atherogenic modifications
of LDL particles in the bloodstream of atherosclerotic
patients [2]. Incubation of native LDL with blood plasma
obtained from atherosclerotic patients results in a
decrease of the sialic acid content of lipoprotein particles
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Fig. 1 Analysis of cholesterol and cholesterol esters contents in native
LDL and cmLDL of healthy donors and coronary atherosclerosis patients.
Presented are the means of 3 independent measurements ± standard
deviation. *, significant difference from native LDL, p< 0.05, §, significant
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Fig. 2 Analysis of main classes of lipids in native LDL and cmLDL of healthy donors and coronary atherosclerosis patients. Presented are the
means of 3 independent measurements ± standard deviation. *, significant difference from native LDL, P < 0.05, §, significant difference from
healthy donors, p < 0.05 (two-tailed Student’s t-test)
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by other physical and chemical modifications including
decrease of the cholesterol, phospholipids and triglycer-
ides contents, decrease of the particle size and increase
of the electrical charge (Table 1). Finally, LDL particles
are oxidized (the level of apoB-bound cholesterol is
increased), which can be explained by possible increased
susceptibility of modified LDL particles to oxidation
resulting from a decreased content of natural antioxi-
dants such as vitamin E (Table 1). LDL atherogenicity,
hence the ability to induce lipid accumulation in
cultured smooth muscular cells and macrophages,
increased with time during the incubation [14]. LDL
acquired atherogenic properties already after 3 h of incu-
bation with blood plasma from atherosclerotic patients
(Table 1), and its atherogenic potential increased during
the incubation until 36 h, when the maximum was
reached [14]. Based on these observations, it can be
proposed that multiple modification of LDL is a cascade
of changes of the lipoprotein particle, which is initiated
by desialylation followed by the decrease of lipid
contents and change of physical parameters (decrease of
particle size, increase of density and electronegativity)
and finalized by oxidation. Every consequent change of
the LDL particle increases its atherogenicity. It is, how-
ever, likely that the input of oxidation to the increase of
the LDL atherogenic potential is minimal.
In this work, we analyzed the lipid composition of
native and desialylated (multiple-modified) LDL isolated
from the blood of atherosclerotic patients. We compared
specifically normally sialylated (native) and desialylated
LDL. Native and desialylated LDL particles are present
in the blood of both healthy individuals and atheroscler-
otic patients. It is important to study the differences of
lipid composition of native and deslaylated LDL in
healthy individuals and atherosclerotic patients. It was
demonstrated that the contents of free and esterified
cholesterol, triglycerides and most of the phospholipids
was decreased in multiply modified LDL in comparison
Table 1 Scheme of LDL modification
1 h 3 h 6 h 12 h 24 h 36 h 48 h
↓ ↑ ↓ ↓ ↓ ↑ ↑
Sialic acid Free cholesterol Size Triglycerides Electronegativity Apo B-bound cholesterol
↑ ↓ ↑
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Fig. 3 Analysis of main classes of phospholipids in native LDL and cmLDL of healthy donors and coronary atherosclerosis patients. Presented are
the means of 3 independent measurements ± standard deviation. *, significant difference from native LDL, P < 0.05, §, significant difference from
healthy donors, p < 0.05 (two-tailed Student’s t-test)
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to native LDL. At the same time, the contents of mono-
and diglycerides and free fatty acids was increased,
probably, as a result of disintegration of triglycerides and
other complex lipids. Importantly, changes of the lipid
composition of naturally occurring circulating multiple-
modified LDL are identical to changes occurring during
incubation of native LDL with blood plasma of
atherosclerotic patients. Such incubation also results in a
decrease of the contents of free and esterified choles-
terol, triglycerides and phospholipids (Fig. 4). This
strengthens the hypothesis that multiple modification of
LDL takes place in the bloodstream.
It has been demonstrated that lipid accumulation in
the arterial wall cells triggers atherogenesis at the cellu-
lar level [2]. Intracellular lipid accumulation is accom-
panied by the pro-inflammatory immune response,
enhanced proliferation and extracellular matrix synthesis
leading to atherosclerotic lesion development and
progression [2]. Taking into account that only multiply-
modified, but not native LDL, causes intracellular lipid
accumulation, it can be concluded that atherosclerosis
development is dependent not so much on the total
LDL level, as on the content of modified LDL. Analytical
methods aimed to measure the level of different forms
of modified LDL in the blood have been developed [15].
However, these methods have not been implemented in
clinical practice so far.
Currently, oxidation is widely regarded as the main, if
not the only form of LDL modification that leads to
formation of atherogenic LDL [16–18]. Our data chal-
lenge this point of view. First, atherogenic properties of
LDL can be associated with other types of modification.
Second, each consequent modification of LDL increases
its atherogenic potential. Third, oxidation is one of the
latest atherogenic modifications in the chain. Fourth,
oxidation does not increase atherogenic potential of
multiple-modified LDL particles any further.
Therefore, multiple modification of LDL is likely to be
the cause of its atherogenicity. Modification of the lipid
composition of LDL represents only one of several
aspects of atherogenic multiple modification of LDL.
Conclusion
The present study demonstrated that cmLDL isolated
from the blood of atherosclerotic patients differs signifi-
cantly from native LDL by its lipid composition. In
particular, cmLDL was characterized by a relative
decrease of free and esterified cholesterol, triglyceride
and phospholipid content and increase of mono- and
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